R-1,3-Butanediol for Colorectal Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
Colorectal Cancer+1 More
R-1,3-Butanediol - DietarySupplement
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The aim of this study is to assess the feasibility of beta-hydroxybutyrate (BHB) supplementation in individuals who are undergoing a standard-of-care colonoscopy or flexible sigmoidoscopy.

Eligible Conditions

  • Colorectal Cancer
  • Colorectal Carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Colorectal Cancer

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Through study completion, which will be approximately 2 years

Year 2
Determine whether oral BHB supplementation is safe and tolerable
Determine whether oral BHB supplementations increases serum BHB levels
Investigate whether oral BHB supplementation leads to transcription and protein expression changes in the colonic mucosa

Trial Safety

Safety Progress

1 of 3

Other trials for Colorectal Cancer

Trial Design

1 Treatment Group

BHB supplementation
1 of 1
Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: R-1,3-Butanediol · No Placebo Group · N/A

BHB supplementation
DietarySupplement
Experimental Group · 1 Intervention: R-1,3-Butanediol · Intervention Types: DietarySupplement

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, which will be approximately 2 years
Closest Location: Abramson Cancer Center of the University of Pennsylvania · Philadelphia, PA
Photo of Philadelphia 1Photo of Philadelphia 2Photo of Philadelphia 3
2006First Recorded Clinical Trial
0 TrialsResearching Colorectal Cancer
259 CompletedClinical Trials

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
345 Previous Clinical Trials
84,462 Total Patients Enrolled
Bryson W Katona, MD, PhDPrincipal InvestigatorUniversity of Pennsylvania
1 Previous Clinical Trials
100 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 18 years old.
You are able to give informed consent.
You are scheduled for a colonoscopy or flexible sigmoidoscopy as part of your standard care.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.